Bio-Techne earns exceptional free cash flow at 274% of net income, holds a Piotroski financial health score of 8 out of 9, and maintains high gross margins — but the Protein Sciences segment represents 72% of revenue, top-line revenue has declined 2% year-over-year, and the stock is trading above its resistance take-profit target with negative asymmetry.
Thesis pillars
- Protein Sciences Segment Concentration↓Deteriorating
- Exceptional Cash Conversion Quality↑Improving
- Revenue Decline With Strong Cash Flow↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Bio-Techne Corp (TECH) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $72.41 — A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Protein Sciences segment (72.0%).
Bio-Techne develops and manufactures life science reagents, instruments, and diagnostics across its Protein Sciences (72% of FY2025 net sales) and Diagnostics and Spatial Biology (28%) segments, selling to pharmaceutical companies, academic researchers, and diagnostic labs... Read more
Sell if holding. Analyst target reached at $72.41 — A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Protein Sciences segment (72.0%). Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Bio-Techne Corp
About Bio-Techne Corp
Bio-Techne's Protein Sciences segment generated approximately 72% of the company's net sales in fiscal 2025, spanning biological reagents, cytokines, antibodies, and automated protein analysis instruments sold under the R&D Systems, Tocris Biosciences, and Novus Biologicals brands. The Diagnostics and Spatial Biology segment contributed the remaining 28%, anchored by spatial genomics tools from Advanced Cell Diagnostics and the Lunaphore acquisition completed at the start of fiscal 2024. Bio-Techne employs approximately 3,100 people globally, about 2,300 of whom are in the United States, and introduced over 400 new products in fiscal 2025.
Bio-Techne earns revenue primarily through direct sales and distribution agreements. In the Protein Sciences segment, the company sells directly to pharmaceutical, biotech, and academic research customers in North America, Europe, and China, with additional distribution through Thermo Fisher Scientific and third-party distributors in Japan, China, and eastern Europe. The Diagnostics and Spatial Biology segment generates revenue from OEM agreements (the majority of Diagnostic Reagents division sales), direct spatial biology instrument and assay sales, and lab-developed test services such as the ExoDx Prostate urine-based assay for prostate cancer detection. Bio-Techne discloses no single end-user customer exceeding 10% of net sales in either segment during fiscal 2025, 2024, or 2023. Approximately 44% of sales revenue in fiscal 2025 came from outside the U.S. Competitive pressure is increasing as pharmaceutical and biotech industry consolidation concentrates purchasing decisions, and manufacturers from Asia have entered certain markets with lower-cost alternatives.
Show full overview
For some laboratory instruments and components requiring specific regulatory qualifications, Bio-Techne may rely on a single supplier or a limited number of suppliers, and the 10-K notes that alternative manufacturing or sourcing is not always available on a timely basis when FDA manufacturing requirements apply. This supply concentration is most visible in instruments and related cartridges. Separately, Bio-Techne plans to acquire the remaining 80.1% stake in Wilson Wolf Corporation by end of calendar 2027, contingent on Wilson Wolf achieving named revenue or EBITDA targets—an obligation the filing estimates could close earlier if milestones are hit, subject to timing uncertainty.
See also: Healthcare · Biotechnology
From Bio-Techne Corp's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-08-15Recent Developments — Bio-Techne Corp
Latest news
- NEWS Dow drops over 1,100 points as sinking tech stocks combine with jumping oil prices to drag markets down - Fortune — Fortune negative
- NEWS Tech stock hits 52-week high at 72.17 USD By Investing.com - Investing.com UK — Investing.com UK positive
- NEWS Some tech shares are plunging - what does that mean for the AI revolution? - BBC — BBC negative
- NEWS Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock? - Yahoo Finance — Yahoo Finance neutral
- NEWS Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock? - finance.yahoo.com — finance.yahoo.com neutral
Generated 2026-08-15T13:12:18Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductProtein Sciences segment72%10-K Item 1: 'The Protein Sciences segment is the larger of our two segments, representing approximately 72% of our net sales in fiscal 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $72.41 — A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Protein Sciences segment (72.0%). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $71.82. Score 4.9/10, moderate confidence.
Take-profit target: $83.26 (-16.2% upside). Prior stop was $71.82. Stop-loss: $71.82.
Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining; Near 52-week high (0.0% away).
Bio-Techne Corp trades at a P/E of 62.4 (forward 31.2). TrendMatrix value score: 3.6/10. Verdict: Sell.
22 analysts cover TECH with a consensus score of 3.5/5. Average price target: $70.
What does Bio-Techne Corp do?Bio-Techne develops and manufactures life science reagents, instruments, and diagnostics across its Protein Sciences...
Bio-Techne develops and manufactures life science reagents, instruments, and diagnostics across its Protein Sciences (72% of FY2025 net sales) and Diagnostics and Spatial Biology (28%) segments, selling to pharmaceutical companies, academic researchers, and diagnostic labs globally. Revenue comes from direct product sales and OEM agreements, with approximately 3,100 employees and operations in North America, Europe, and Asia.